BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22209376)

  • 1. Novel molecular targets for the therapy of castration-resistant prostate cancer.
    Agarwal N; Sonpavde G; Sternberg CN
    Eur Urol; 2012 May; 61(5):950-60. PubMed ID: 22209376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The treatment of castration-resistant prostate cancer].
    Petrányi Á
    Magy Onkol; 2012 Dec; 56(4):219-28. PubMed ID: 23236591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I; Ravery V; Pouessel D; Culine S
    Prog Urol; 2013 Jan; 23(1):1-7. PubMed ID: 23287477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H; Bahl A; Mason M; Troup J; De Bono J
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel therapies for metastatic castrate-resistant prostate cancer.
    Dayyani F; Gallick GE; Logothetis CJ; Corn PG
    J Natl Cancer Inst; 2011 Nov; 103(22):1665-75. PubMed ID: 21917607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents for prostate cancer.
    Agarwal N; Di Lorenzo G; Sonpavde G; Bellmunt J
    Ann Oncol; 2014 Sep; 25(9):1700-1709. PubMed ID: 24658665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Strategy in advanced castration-resistant prostate cancer].
    Gross-Goupil M; Roca S; Pasticier G; Ravaud A
    Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Management of metastatic castration-resistant prostate cancer following docetaxel].
    Beuzeboc P; Ropert S; Goldwasser F; Zerbib M
    Bull Cancer; 2012 Jul; 99 Suppl 1():S66-72. PubMed ID: 22516457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metastatic castration-resistant prostate cancer: time for innovation.
    Tucci M; Scagliotti GV; Vignani F
    Future Oncol; 2015; 11(1):91-106. PubMed ID: 25572785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New hope in the treatment of advanced cancer of the prostate in 2012].
    Massard C
    Bull Cancer; 2012 Jul; 99 Suppl 1():S3. PubMed ID: 23767051
    [No Abstract]   [Full Text] [Related]  

  • 12. Novel and bone-targeted agents for CRPC.
    Fizazi K; Albiges L; Massard C; Escudier B; Loriot Y
    Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathologic fracture in patients with metastatic prostate cancer.
    Gartrell BA; Saad F
    Curr Opin Urol; 2014 Nov; 24(6):595-600. PubMed ID: 25166424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
    Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
    Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
    Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatment options for patients with metastatic prostate cancer.
    Snoeks LL; Ogilvie AC; van Haarst EP; Siegert CE
    Neth J Med; 2013; 71(6):290-4. PubMed ID: 23956309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical development of novel therapeutics for castration-resistant prostate cancer: historic challenges and recent successes.
    Galsky MD; Small AC; Tsao CK; Oh WK
    CA Cancer J Clin; 2012; 62(5):299-308. PubMed ID: 22535487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing landscape in metastatic castration-resistant prostate cancer.
    Leibowitz-Amit R; Joshua AM
    Curr Opin Support Palliat Care; 2013 Sep; 7(3):243-8. PubMed ID: 23817317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How to manage patients with CRPC?].
    Beuzeboc P; Massard C
    Bull Cancer; 2015 Jun; 102(6):509-15. PubMed ID: 26028494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.